Healthcare deep-tech startups often celebrate the moment a diagnostic prototype finally works inside the lab. Yet in the diagnostics industry, proving that a device can work once is often far easier than proving it can work repeatedly across thousands or millions of units. As healthcare systems push for faster and more decentralized testing, manufacturing reproducibility is emerging as one of the most underestimated challenges in diagnostic commercialization.
A Working Prototype Does Not Prove Manufacturing Readiness
The diagnostics industry has spent years accelerating development of point-of-care systems, biosensors, and decentralized healthcare testing platforms. However, scaling these technologies into stable manufacturing systems remains a very different problem from proving scientific feasibility.
According to theU.S. Food and Drug Administration (FDA),medical-device manufacturers must establish quality-management systems capable of consistently meeting product specifications and process requirements.
The agency’s updated Quality Management System Regulation (QMSR), which became effective in 2026, further aligned device manufacturing expectations with ISO 13485 quality-management standards.
For diagnostics developer Hyou-Arm Joung, CTO and Co-Founder of Kompass Diagnostics, this distinction between invention and industrial reproducibility is often misunderstood inside healthcare startups.
“A working prototype only proves that the technology is possible.”
As discussion on the growing gap between diagnostic prototypes and real-world manufacturing scalability continues, Joung told ngopihangat,
“Manufacturing is a completely different challenge. It is about whether the optimal conditions can be maintained consistently over time, scale, and process variation.”
Joung’s experience spans diagnostic commercialization work in both Korea and the United States, including biosensor research, point-of-care diagnostic development, and large-scale manufacturing execution.
Diagnostic Manufacturing Faces Hidden Variables That Often Appear Late
Unlike many software-driven healthcare systems, diagnostic manufacturing depends heavily on controlling biological, chemical, mechanical, and environmental variability simultaneously.
Joung explained that many critical manufacturing problems only emerge during production scale-up.
“For example, even high-performance dispensers gradually change their behavior over time due to wear, contamination, or calibration drift,”
he said.
“In many cases, the correct maintenance schedule and process limits are not fully defined by the equipment manufacturer, but instead must be learned through empirical manufacturing experience specific to the product.”
The FDA’s process-validation framework similarly emphasizes that manufacturing systems must demonstrate long-term consistency and reduced process variation, not simply isolated product performance during development.
That challenge becomes particularly severe in diagnostics because small production inconsistencies can directly affect medical results.
Scientific literature examining immunoassay manufacturing has also warned that lot-to-lot variation in raw materials and manufacturing processes can alter assay accuracy, precision, and reproducibility. In biosensor systems, additional instability can emerge from biological recognition materials themselves, including degradation, denaturation, contamination, and storage sensitivity.
Joung believes many of these risks remain underestimated during early-stage startup development.
“In reality, there are countless hidden variables that begin to appear only during scale-up.”
Biological Materials Create a Different Manufacturing Problem
Diagnostic manufacturing becomes even more difficult because biological materials often behave unpredictably outside controlled laboratory workflows.
Joung explained that laboratory-stage development usually operates under short preparation and usage cycles, while commercial manufacturing introduces much longer production timelines.
“In laboratory development, reagents are usually prepared and consumed very quickly,”
he said.
“But in manufacturing, large batches may need to remain stable for many hours before use. The behavior of biological materials under these conditions often cannot be predicted theoretically. It must be understood through real production testing and accumulated process knowledge.”
That accumulated process knowledge can take years to build.
Joung recalled his earlier experience commercializing a cholesterol diagnostic system during his time in Korea’s diagnostics industry.
“The core product development took about two years, but achieving a manufacturing process with over 95% production yield required nearly seven years.”
The statement reflects a broader challenge facing healthcare deep-tech startups globally. Many investors and founders focus heavily on prototype validation, intellectual property, and early analytical performance. However, industrial reproducibility often determines whether a technology can survive commercialization long-term.
FDA guidance on process validation similarly defines manufacturing validation as scientific evidence that a production process can consistently deliver quality products throughout the product lifecycle.
Korea’s Diagnostic Industry Still Faces the Manufacturing Maturity Challenge
Korea has developed strong manufacturing infrastructure across multiple industrial sectors, including semiconductors, electronics, and biotechnology. The country has also continued refining its in vitro diagnostic manufacturing and quality-management standards under the Ministry of Food and Drug Safety (MFDS).
However, diagnostic commercialization remains structurally demanding because medical-device manufacturing combines biological variability, regulatory compliance, process control, and long-term quality assurance simultaneously.
For startups, this creates an uncomfortable reality. Early technical success can still fail commercially if manufacturing variability cannot be controlled consistently over time.
The issue is becoming increasingly important as decentralized diagnostics continue expanding globally. Point-of-care and at-home systems require manufacturers to maintain reliability outside tightly controlled laboratory conditions while still achieving cost competitiveness and scalable production.
Joung believes this industrial discipline is often underestimated during early innovation cycles.
“Scaling is not simply about reproducing a prototype,”
he said.
“It is about building a manufacturing system capable of continuously controlling variability, stability, and reproducibility at industrial scale.”
The Hardest Part of Healthcare Deep-Tech May Come After the Breakthrough
So yes, healthcare startups often present innovation as a race toward technological breakthroughs. Yet diagnostics commercialization may depend less on discovering a new sensing mechanism and more on maintaining reliable production consistency under industrial conditions.
That challenge extends far beyond hardware assembly alone. It includes supplier consistency, process drift, biological-material stability, equipment calibration, environmental controls, validation procedures, and long-term quality monitoring across large-scale deployment.
As regulators continue strengthening manufacturing-quality expectations and healthcare systems push diagnostics closer to patients, industrial reproducibility may become one of the defining competitive barriers in healthcare deep-tech.
For many diagnostic startups, the hardest stage may begin only after the prototype finally works.
Key Takeaways
- A functional diagnostic prototype does not guarantee manufacturing readiness or commercial scalability.
- According to Hyou-Arm Joung, diagnostic manufacturing becomes difficult because production systems must maintain long-term reproducibility, stability, and process control under industrial conditions.
- FDA manufacturing guidance increasingly emphasizes process validation, quality-system controls, and reduced production variability throughout the product lifecycle.
- Diagnostic manufacturing faces hidden risks including equipment drift, raw-material variation, reagent instability, contamination, and process inconsistency.
- Joung stated that commercializing a cholesterol diagnostic platform required about two years for core product development but nearly seven years to achieve over 95% manufacturing yield.
- The expansion of decentralized diagnostics is increasing pressure on manufacturers to deliver stable large-scale production outside tightly controlled laboratory environments.
- Healthcare deep-tech commercialization increasingly depends on industrial reproducibility and accumulated manufacturing process knowledge, not only scientific innovation.
🤝 Looking to connect with verified Korean companies building globally?
Explore curated company profiles and request direct introductions through beSUCCESS Connect.
– Stay Ahead in Korea’s Startup Scene –
Get real-time insights, funding updates, and policy shifts shaping Korea’s innovation ecosystem.
➡️ Follow ngopihangat on LinkedIn, X (Twitter), Threads, Bluesky, Telegram, Facebook, and WhatsApp Channel.
PakarPBN
A Private Blog Network (PBN) is a collection of websites that are controlled by a single individual or organization and used primarily to build backlinks to a “money site” in order to influence its ranking in search engines such as Google. The core idea behind a PBN is based on the importance of backlinks in Google’s ranking algorithm. Since Google views backlinks as signals of authority and trust, some website owners attempt to artificially create these signals through a controlled network of sites.
In a typical PBN setup, the owner acquires expired or aged domains that already have existing authority, backlinks, and history. These domains are rebuilt with new content and hosted separately, often using different IP addresses, hosting providers, themes, and ownership details to make them appear unrelated. Within the content published on these sites, links are strategically placed that point to the main website the owner wants to rank higher. By doing this, the owner attempts to pass link equity (also known as “link juice”) from the PBN sites to the target website.
The purpose of a PBN is to give the impression that the target website is naturally earning links from multiple independent sources. If done effectively, this can temporarily improve keyword rankings, increase organic visibility, and drive more traffic from search results.
